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9 Abstract 
10 
11 
12 Purpose 
13 
14 New  hepatitis  C  medicines  such  as  sofosbuvir  underline  the  need  to    balance 
15 considerations of innovation, clinical evidence, budget impact and equity in   health 
16 
17 priority-setting.  This article examines the role of public participation  in addressing 
18 
19 these considerations. 
20 
21 
22 Design/Methodology/Approach 
23 
24 The article employs a comparative case study approach. It explores the experience of 
25 four  countries–Brazil,  England,  South  Korea  and  the  USA–in  making coverage 
27 decisions about the antiviral sofosbuvir and involving the public and patients in these 
28 
29 decision-making processes. 
30 
31 
32 Findings 
33 
34 Issues emerging from public participation activities include the role of the universal 
35 right to health in Brazil, the balance between innovation and budget impact in 
36 
37 England,  the  effect  of  unethical  medical  practices  on  public  perception  in    South 
38 
39 Korea,  and  the  legitimacy  of  priority-setting  processes  in  the  USA.  Providing 
40 policymakers are receptive to these issues, public participation activities may be re- 
42 conceptualized as processes that  illuminate  policy problems  relevant  to  a particular 
43 
44 context, thereby promoting an agenda-setting role for the   public. 
45 
46 
47 Originality/Value 
48 
49 The  article  offers  an  empirical  analysis  of  public  involvement  in  the  case   of 
50 sofosbuvir, where the relevant considerations that bear on priority-setting  decisions 
52 have   been   particularly   stark.   The   perspectives   that emerge   suggest   that public 
53 
54 participation contributes to raising attention to issues that need to be addressed by 
55 policy-makers.  Public  participation activities can  thus  contribute  to  setting policy 
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1 
2 
3 Introduction 
4 
5 
6 In  2013  the  Food  and  Drug  Administration  (FDA)  in  the  United  States  of 
7 
8 America  (USA)  approved  sofosbuvir  and  simeprevir  for  the  treatment  of    chronic 
9 
10 hepatitis C infections (FDA, 2014). The regulatory agencies of other countries soon 
11 followed and the use of sofosbuvir was approved by the European Medicines Agency 
12 
13 (EMA)  in  January  2014  (EMA,  2015).  These  medicines,  along  with  a  third called 
14 
15 daclatasvir, were hailed as a breakthrough in the treatment of patients with   chronic 
16 hepatitis C as they are considered to be highly effective antiviral agents that, for the 
17 
18 first time, attack the hepatitis C virus (HCV) directly. These drugs are not only more 
19 
20 effective in achieving sustained virological response–effectively curing patients–but 
21 also have fewer side effects than previous treatments. Unsurprisingly, there has been 
22 
23 high  demand for  these  new “cures” for  hepatitis C  among  patients–especially  given 
24 
25 the   alternative   prospects   of   deteriorating   liver   function   and   possible   liver 
26 transplantation  or  death,  alongside  the  psychological  distress  and  social stigma 
27 
28 attached to the disease (Vietri et al, 2013; Younossi and Henry,   2015). 
29 
30 However, the new HCV medicines come at a price. It is a price that most 
31 countries struggle to afford, regardless of their wealth or the structure of their health 
32 
33 system. The actual price of the regimen is hard to unveil because many health care 
34 
35 systems engage in confidential negotiations with pharmaceutical manufacturers  for 
36 discounted prices, but a 12-week treatment with sofosbuvir has been estimated to cost 
37 
38 as  much  as  $84,000  in  the  USA  (McCarthy,  2015).  Policymakers  or  insurers face 
39 
40 difficult decisions on whether to cover these novel and costly medicines, weighing the 
41 benefits these  drugs could  offer against the  opportunity costs of securing     health 
42 
43 benefits for the  broader population.  Such challenges  raise questions about what    role, 
44 
45 if any, patients and the public have in priority-setting decisions for new and expensive 
46 drugs. This article outlines how the highly innovative, but very expensive, new 
47 
48 hepatitis   C   medicines   have   exacerbated   the   challenge   of   making prioritization 
49 
50 decisions in health care and explores the role of patient and public involvement (PPI) 
51 in addressing this challenge. 
52 
53 The  focus of  the  article arises from  deliberations held at  a  workshop  at    the 
54 
55 Brocher Foundation in Switzerland in November 2015. The workshop was dedicated 
56 to exploring ways to improve equitable access to health care through increasing 
57 
58 public   and   patient   involvement   in   prioritization   decisions.   It   brought  together 
59 
60 
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1 
2 
3 academic and policy experts in health priority-setting and    public involvement from 12 
4 
5 countries. Its purpose was to exchange knowledge    and observations about country 
6 experiences of PPI in priority-setting. One of the observations emerging from the 
7 
8 deliberations  was  that  the   new  HCV  medicines  seem  to   have   exacerbated      the 
9 
10 challenge of making fair prioritization decisions because of the complex set of issues 
11 around innovation, clinical evidence and budget impact to which they give rise. This 
12 
13 article  asks what  role,  if  any,  public  involvement has played  in  alleviating some  of 
14 
15 these issues. How have countries involved the public and patients in addressing  the 
16 question of how to secure equitable access to new hepatitis C medicines? What  can 
17 
18 we learn from this  experience? 
19 
20 In the extant literature, the importance of involving the public in health 
21 priority-setting is  explained with reference  to the complex and    multiple  relevant 
22 
23 considerations  that  can  bear  on  decisions.  For  example,  to  justify  the  model      of 
24 
25 “accountability for reasonableness”, Daniels and Sabin (1997) argue    that priority- 
26 setting  institutions  must  ensure  fair  processes.  Because  more  than  one relevant 
27 
28 consideration  generally  bears  on  priority-setting  questions,  relevant    considerations 
29 
30 often conflict and there is no consensus among decision-makers, commentators or the 
31 public at large as to how to trade them off against each other. Daniels and Sabin give 
32 
33 PPI a role in ensuring fair process and many commentators argue that it should take 
34 
35 center-stage (Emanuel, 2002; Friedman, 2008; Rid, 2009; Sabik and Lie, 2008). 
36 This  article  contributes  to  the  existing  debates  by  offering  an empirical 
37 
38 analysis   of   public   involvement   in   the   case   of   sofosbuvir,   where   the relevant 
39 
40 considerations that bear on priority-setting decisions have been particularly stark. It 
41 examines how the public has been involved in decisions on new HCV medicines  in 
42 
43 four   countries   (Brazil,   England,   South   Korea   and   the   USA),   thereby  offering 
44 
45 comparative insights on how different health systems involve the public in complex 
46 priority-setting problems, and on the perspectives that emerge. Perspectives that 
47 
48 emerge include the role of the universal right to health in Brazil, the balance between 
49 
50 innovation and budget impact in England, the effect of unethical medical practices on 
51 public perception in South Korea, and the legitimacy of priority-setting processes in 
52 
53 the  USA.  Although  these  issues  are  contextual  and  not   necessarily  novel  in    the 
54 
55 individual  contexts,  they  appear  more  pronounced  in  the  case  of  sofosbuvir. If 
56 policymakers  are  aware  of,  and  receptive  to,  these  issues,  public  participation 
57 
58 activities may be usefully re-conceptualized as processes that illuminate    salient policy 
59 
60 
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1 
2 
3 problems  relevant  to  a  particular  context,  thereby supporting  an  agenda-setting role 
4 
5 for the public. The actualization of this role is highly contingent on policymakers 
6 being receptive to the issues. Given the important perspectives that emerged in   the 
7 
8 case of sofosbuvir, this article concludes that further research is necessary on whether 
9 
10 they have found traction in the public policy arenas of Brazil, England, South Korea 
11 and the USA. 
12 
13 The  article  proceeds   by  providing  a  brief  conceptual  overview  of     health 
14 
15 priority-setting and PPI, the methods and data for the case studies, the new HCV 
16 medicines generally, and of sofosbuvir particularly. These sections set the scene for 
17 
18 the discussions of the country case studies and the conclusion in the latter parts of the 
19 
20 article. 
21 
22 
23 Health Priority-Setting and Patient and Public   Involvement 
24 
25 
26 Setting priorities in health care holds a prominent place on the policy agenda 
27 
28 in  countries  around  the  world,  particularly  as  countries  seek  to  achieve   universal 
29 
30 health  coverage.  The  advent  of  this  agenda,  including  the  creation  of     health 
31 technology assessment (HTA) organizations, has brought about an increased interest 
32 
33 in the role of PPI in health prioritization (e.g. Martin et al., 2002; Abelson et al., 
34 
35 2007) because decisions involve making difficult choices that cannot be made solely 
36 on technical grounds and hence need to be justified and legitimized in the context of 
37 
38 social  values  and  procedural  justice  (Clark  and  Weale,  2012;  Daniels  and    Sabin, 
39 
40 1997). 
41 Regardless of where priority-setting takes place, it is concerned with making 
42 
43 decisions that provide a good quality, and a fair, health service while ensuring that the 
44 
45 health system is sustainable. The extant literature suggests that public input into the 
46 choices made should be included as one important criterion against which to  assess 
47 
48 the fairness of prioritization decisions (Sibbald et al., 2009; Kapiriri and Martin,    2010; 
49 
50 Sabik and Lie, 2008). However, barriers to public involvement exist (Goold et al., 
51 2005) and little empirical evidence is available on the effect of PPI generally, and 
52 
53 different modes of PPI such as deliberative processes specifically (Mitton et al., 2009; 
54 
55 Abelson et al., 2003). 
56 This  article  follows  Weale  et  al.’s  (2016,  p.   5)  definition  of       public 
57 
58 participation in priority-setting as involving “[…] individuals or groups  taking part    in 
59 
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1 
2 
3 processes of policy making that shape the determination of priorities in health care 
4 
5 and  the  conditions  of  access  of  different  groups  in  society”.  It  is collectively- 
6 orientated and excludes forms of patient involvement such as involvement in research 
7 
8 or  shared decision-making as  these forms  of  involvement  are  not aimed at   bringing 
9 
10 about a decision that affects public policy at large. This collectively-orientated mode 
11 of public participation can come in different forms such as the inclusion of patient or 
12 
13 public representatives in HTA  bodies,  mini-publics or consultative  forums    convened 
14 
15 to garner public and patient views. Importantly, it also includes more unconventional 
16 forms of public participation such as protests, demonstrations, public campaigns and 
17 
18 litigation. To include these forms of involvement is  crucial because in some    countries 
19 
20 they have become a routinized mode of involvement that can affect  priority-setting 
21 decisions (Weale et al., 2016; Slutsky et al., 2016). 
22 
23 
24 
25 Methods and Data 
26 
27 
28 The  article  employs  a  comparative  case  study  approach.  Its  main  units   of 
29 
30 analysis  are  the  country-specific  processes  of public  participation in the  case of 
31 sofosbuvir. We focus on sofosbuvir because it has received substantial attention   in 
32 
33 media  outlets  worldwide.  The  country  case  selection  was  informed  by  the  aim  to 
34 
35 include countries with conventional and unconventional modes of public participation 
36 in health prioritization (Weale et al., 2016). For reasons of data availability, the 
37 
38 selection   was   restricted   to   the   countries   represented  at  the   Brocher Foundation 
39 
40 workshop entitled “Improving equitable access to health care through patient and 
41 public involvement in prioritization decisions” in Switzerland in November 2015. The 
42 
43 represented   countries   were   Australia,   Brazil,   China,   Colombia,   Germany,  New 
44 
45 Zealand, South Africa, South Korea, Sri Lanka, Thailand, the United Kingdom (UK) 
46 and the United States of America (USA). 
47 
48 Following   Slutsky’s   et   al.’s   (2016)   distinction   between   consensus,    i.e. 
49 
50 conventional, and contestatory participation, i.e. unconventional, modes of 
51 participation, Brazil, England, South Korea and the USA were selected as cases. 
52 
53 England   represents   a   system   where   contestatory   participation   is   not routinized 
54 
55 (Slutsky et al., 2016), whereas Brazil and South Korea represent countries where it is 
56 routinized. The USA represent a unique case in that participation is neither   clearly 
57 
58 consensus nor contestatory-based because of a  lack of federal prioritization     decision- 
57 
58 
59 
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1 
2 
3 making in which the public participates in a routine fashion. Nevertheless, as we shall 
4 
5 see, forums for participation do exist in the form of institutes such as the Institute for 
6 Clinical and Economic Review (ICER). 
7 
8 The  article  draws on country  data  on  PPI and  health priority-setting that was 
9 
10 presented at the Brocher Foundation workshop. This data was supplemented by data 
11 from secondary literature. At the workshop policy and academic experts presented the 
12 
13 status quo of health priority-setting and PPI in their countries following a template of 
14 
15 nine areas (see http://www.ucl.ac.uk/socialvalues for presentations): 
16 1) Overview of health system and approaches to prioritization; 
17 
18 2) Degree and nature of PPI in  prioritization; 
19 
20 3) Rationale for PPI; 
21 4) Successes and challenges; 
22 
23 5) A prioritization case study and impact of PPI in this   case; 
24 
25 6) Issues highlighted by the case study; 
26 7) Ethical or social values questions in relation to PPI; 
27 
28 8) Lessons learnt; 
29 
30 9) Future plans for PPI in  prioritization. 
31 
32 
33 In its discussion of the country cases, this article broadly follows the outlined 
34 
35 template.  Each case study  begins  with a  brief  overview  of  the health system and 
36 approaches to PPI in health prioritization. A discussion of the rationale as well as the 
37 
38 successes  and challenges  of  PPI  is  omitted because the focus is on the   prioritization 
39 
40 case study (sofosbuvir) and the issues, ethical questions and lessons learnt.    Unless 
41 they emerge directly from PPI in the case of sofosbuvir, the category of future plans 
42 
43 for PPI is also omitted for the purpose of this  paper. 
44 
45 Due to the small number of cases included in this article, the generalizability 
46 of the observations is limited. However, the purpose of this article is not to bring forth 
47 
48 generalizable  claims,  but  to  provide  an  insight  into  the  role  PPI  has  played       in 
49 
50 coverage decisions on new HCV medicines. This is to gain a better understanding of 
51 the contributions of PPI activities in complex prioritization decisions. 
52 
53 
54 
55 
56 
59 
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1 
2 
3 New HCV medicines 
4 
5 
6 “Hepatitis C is a virus that can infect the liver” (NHS Choices, 2015). Long- 
7 
8 term, and potentially life-threatening complications from chronic hepatitis C    infection 
9 
10 include liver cirrhosis and liver cancer. More than 185 million people are affected by 
11 hepatitis C and approximately 350,000 people die each year as a consequence (WHO, 
12 
13 2014, p. 25). Hepatitis C is transmitted through contact with infected blood specimens 
14 
15 (WHO,  2014).  There  are  several  types  and  subtypes  of  the  infection, so-called 
16 genotypes. 
17 
18 In  recent years a  rapid  development in treatments for chronic hepatitis C    has 
19 
20 taken  place.  In  2011  and  2012  the  medicines  telaprevir  and  boceprevir    were 
21 introduced. Since 2013 additional medicines have been approved around the  world, 
22 
23 namely  sofosbuvir,   simeprevir  and  daclatasvir.   These   medicines  are   direct-acting 
24 
25 antivirals (DAAs) that target the HCV itself, an innovation over previous treatments 
26 that indirectly suppressed the virus through inhibiting its replication. 
27 
28 This  article  focuses  on  sofosbuvir.  The  main  clinical  endpoint  measured in 
29 
30 randomized  controlled  trials  (RCTs)  on  hepatitis  C  medicines  is  the  sustained 
31 virological response (SVR), that is the virus being undetectable in the blood three or 
32 
33 six months after treatment (WHO, 2014). Sofosbuvir achieved a SVR in over 90% of 
34 
35 the patients across different genotypes of hepatitis C (WHO, 2014). Clinical experts 
36 equate the achievement of a SVR to a cure (NICE, 2015, p. 46). Arguably, providing 
37 
38 a drug like sofosbuvir would not only yield benefits for patients, but also avert future 
39 
40 high costs associated with liver transplants as well as generate public health benefits 
41 through  reduced  HCV  transmission.  However,  there  is  still  much    uncertainty 
42 
43 surrounding the potential of future (liver) complications for patients who have cleared 
44 
45 the virus or the question of which patients would progress to more serious stages  of 
46 liver disease if left untreated. Trials on sofosbuvir report fewer, and less severe, side 
47 
48 effects as well as a potential reduction of the treatment cycle from 24-48 weeks to as 
49 
50 little as 12 weeks (WHO, 2014). Additionally, sofosbuvir is administered orally in the 
51 form of a pill once a day for usually 12 weeks, whereas previous methods of 
52 
53 administration were mostly through  injections. 
54 
55 However,  at an estimated  price of  $84,000 for a  12-week treatment in  the 
56 USA, sofosbuvir has been labeled the $1,000 pill (McCarthy, 2015). The first WHO 
57 
58 guidelines   on   the   screening,   care   and   treatment   of   patients   with   hepatitis   C 
57 
58 
59 
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1 
2 
3 recommend access to the new medicines. In the absence of sufficient funds to   treat the 
4 
5 entire patient population, they recommend to treat the sickest patients first   (WHO, 
6 2014). This is the way a number of countries have approached the access, for example 
7 
8 guidelines in the USA and England recommend to treat patients with cirrhosis first 
9 
10 (McCarthy, 2014; NICE  2015). 
11 The   challenge   of    providing   access   to   these   new   medicines     includes 
12 
13 considerations of cost effectiveness, affordability, health equity, public  health and    the 
14 
15 ethical implications of treating the sickest patients first. One of the biggest issues  is 
16 how to resolve the perceived tension between cost effectiveness and affordability. The 
17 
18 approach to prioritization in many tax-based health systems focuses on the    assessment 
19 
20 of cost effectiveness, with an assumption - explicit or implicit - that treatments should 
21 be  made  available  to  all  patients  for  whom  they  deliver  outcomes  whose cost 
22 
23 effectiveness exceeds a pre-determined threshold. But when the total    budget impact of 
24 
25 such  a  treatment  is  large,  its  adoption  may  require  significant  re-direction   of 
26 resources, either from other areas of health spending, and/or from areas of non-health 
27 
28 expenditure  (Claxton  et  al.,  2015;  Ward,  2015).  A  re-direction  of  resources  raises 
29 
30 questions of equity with regard to the patient groups who lose out as a result. It 
31 therefore requires debate and resolution in the political space, which may or may not 
32 
33 include the wider public. 
34 
35 The above issues are complicated by the fact that Hepatitis C is already 
36 strongly associated with health inequities. It disproportionately affects populations in 
37 
38 low and middle income countries (Graham and Swan, 2015), which to date have not 
39 
40 had  much  access  to  available  treatments  due  to  the  challenging  screening  and 
41 monitoring requirements. Moreover, sofosbuvir and other DAAs have been labeled a 
42 
43 cure, a label that few other medical innovations achieve. Familiar issues of pricing 
44 
45 and the current patent system are also surfacing. For example Argentina, Brazil, 
46 China, Russia and the Ukraine are challenging the current patent for the new hepatitis 
47 
48 C  drugs  (Bagcchi,  2015).  Similarly,  a  non-governmental  organization  of  doctors in 
49 
50 France that provides healthcare for vulnerable populations worldwide, the Médecins 
51 du Monde, is challenging the patent at the European Patent Office (EPO)  (Boseley, 
52 
53 2015).   Given  this  mix  of  complex  issues,  the   question  arises  if   PPI   can     help 
54 
55 adjudicate between the different issues. What has the experience of involving the 
56 public and patients been in the case of sofosbuvir? 
  
 
 
1 
2 
3 Public Participation in the Case of  Sofosbuvir 
4 
5 
6 Brazil 
7 
8 
9 
10 The  Brazilian  Public  Health  System,  better  known  by the  acronym SUS 
11 (Sistema Único de Saúde; Unified Health System) was established under the Federal 
12 
13 Constitution of  Brazil in 1988.  Enshrined in the Constitution is a  right  to health   care 
14 
15 and a governmental duty to guarantee universal and equal access to services and 
16 activities that promote, protect and restore health (Paim et al., 2011). Brazil’s forums 
17 
18 for  public  participation  include  municipal  and  state  health  councils  comprised    of 
19 
20 members of the public and patient representatives. Through these councils health care 
21 planners are  held to account  by  the citizenry  (Dall’Agnol  Modesto et al.,   2007). 
22 
23 Brazil’s  tradition  of  public  involvement  is  also  reflected  in  the  way  the  public  is 
24 
25 involved in the SUS. The National Health Council, which consists of a mix of 
26 representatives of service user organizations (50%), health care worker 
27 
28 representatives (25%), government and health service providers (25%), holds    monthly 
29 
30 meetings in which proposals are deliberated (Dall’Agnol Modesto et al., 2007). 
31 In   the   case   of   sofosbuvir,   the   National   Commission  on Technology 
32 
33 Incorporation in the National Health System (CONITEC), the HTA body in Brazil, 
34 
35 decided  unanimously  to  recommend the  inclusion  of  sofosbuvir,  daclatasvir and 
36 simeprevir for the treatment of chronic HCV (CONITEC, 2015). The 
37 
38 recommendation  was  preceded  by  a   public  consultation   on  HTA  report.     Public 
39 
40 contributions were made through submissions to the CONITEC website. 
41 During the process of assessing sofosbuvir, CONITEC also presented revised 
42 
43 Clinical  Protocol  and  Therapeutic  Guidelines  (PCDT)  for  the  disease,  with      new 
44 
45 guidance on treating the condition. The assessment process did not evoke as    much 
46 public protest and engagement as did the revised PCDT. According to the revised 
47 
48 protocol, the degree of fibrosis determines the group of patients who are eligible to be 
49 
50 treated with the new antiviral agents under the SUS,  excluding patients at    fibrosis 
51 stages F1 and F2 (PCDT, 2015). 
52 
53 The   Brazilian  Movement   of  the   Fight   against  Viral   Hepatitis  voiced  its 
54 
55 dissatisfaction with the protocol and invoked the constitutional universal right to 
56 health, claiming that the patient groups included in the protocol “represent less  than 
57 
58 4%  of  the  current need and means  tearing the  principle  of universality of  access   to 
  
 
 
1 
2 
3 health”
1  
(MBHV,  2015). The  official estimate is  that 60,000 patients  will be    treated 
4 
5 with sofosbuvir in the next two years. To the Work Group of Intellectual Property 
6 (GTPI), “this is less than 1/3 of the related demand […]” (GTPI, 2015). 
7 
8 The  fact  that  the  Brazilian  Movement  of  the  Fight  against  Viral   Hepatitis 
9 
10 invoked the constitutional universal right to health reflects a prominent feature of 
11 many health systems in Latin America where the right to health is enshrined in   the 
12 
13 Constitution.  Reimbursement  decisions  on  medicines are  made  through  benefit plan 
14 
15 assessments (BPA), following the principles of financial sustainability and of clinical 
16 efficiency. For a molecule to be considered for BPA, it generally has to overcome the 
17 
18 HTA  hurdle.  In  order  to  ensure  financial  sustainability  some  countries       perform 
19 
20 different  degrees  of Budget  Impact  Analysis  (BIA)  (e.g.  Ministerio de  Salud de 
21 Colombia, 2015). In this setting there is an inherent tension between the HTA results 
22 
23 and the BPA results that may yield that a cost effective technology is unaffordable for 
24 
25 the  entire  system,  which  is  why  CONITEC  recommended  restricting  access to 
26 sofosbuvir according to fibrosis stage. 
27 
28 Given  the  constitutional  protection  of  the  right  to  health,  Latin    American 
29 
30 individuals and campaign groups can resort to courts to challenge the results of   the 
31 HTA   and   BPA.   Every   year   thousands   of   Latin   Americans   resort   to  this 
32 
33 unconventional  form  of  PPI  and  more  often  than  not  judges  rule  in  favor  of   the 
34 
35 avalanche of plaintiffs (Cubillos et al., 2012). The effect that easy litigation has on the 
36 incentives to participate in the more established PPI mechanisms is unclear. If one can 
37 
38 almost certainly win a case in less than two weeks, why join a process that may take 
39 
40 months or years and that may not lead to your desired outcome? Policymakers in 
41 Latin America continue to grapple with the constraining effects of the constitutional 
42 
43 right to health on priority-setting  decisions. 
44 
45 
46 England 
47 
48 
49 
50 The  National  Health System  (NHS)  is a tax-based health  system in which 
51 national and local structures share decision-making responsibility. At local level, 211 
52 
53 clinical  commissioning  groups  (CCGs)  are  responsible  for  commissioning (Thorlby 
54 
55 and Arora, 2014), i.e. buying, health services from public, private or non-profit health 
56 
57    
58 1 Translated by one of the authors of this article. 
  
 
 
1 
2 
3 care providers.  At the national level,  NHS England oversees spending and    allocation 
4 
5 of resources (NHS England, 2016). CCGs and NHS England are supported by the 
6 National Institute for Health and Care Excellence (NICE), an organization responsible 
7 
8 for appraising the clinical  and cost effectiveness of  new medicines.  If  NICE makes   a 
9 
10 positive  recommendation  on a  new  drug,  then commissioners  are  under  a legal 
11 obligation to make the treatment available (NICE, 2016). NICE makes its appraisals 
12 
13 on the basis of clinical and cost effectiveness considerations as well as social value 
14 
15 judgements (Rid et al., 2015). 
16 NICE conducts a public consultation process for every treatment it appraises. 
17 
18 In this process there are two groups that are allowed to participate, namely consultees 
19 
20 and commentators. Consultees include patient and professional organizations,     the 
21 pharmaceutical  manufacturer,  government  and NHS  entities (NICE,  2013,  p. 4). 
22 
23 Commentators include manufacturers of comparator technologies or research groups 
24 
25 who are allowed to comment, but do not have a right to appeal the decision. The 
26 wider public can submit comments on NICE’s website (NICE, 2016a). 
27 
28 NICE made a positive recommendation for the use of sofosbuvir, although    the 
29 
30 use of sofosbuvir in genotypes 4, 5 and 6 was only recommended in patients  whose 
31 infection had already progressed  to liver cirrhosis (NICE, 2015). The    contentious 
32 
33 issues did not arise as a result of NICE’s appraisal of sofosbuvir, but as a result of 
34 
35 NICE’s decision to grant NHS England an extension to the normal   implementation 
36 period in which a NICE-recommended treatment has to be made available on the 
37 
38 NHS. Usually NHS commissioners have to ensure that patients receive access to the 
39 
40 recommended treatment within three months after it has been recommended (NICE, 
41 2016). In the case of sofosbuvir a waiver of this period was sought by NHS England 
42 
43 (NICE,  2014a).  Four  reasons  were  provided:  First,  NHS  England  argued  that   the 
44 
45 health service had to be reworked in order to provide access to the new medicines 
46 through specialized treatment centers. Second, a substantial increase in demand  for 
47 
48 treatment could be expected, making it necessary for NHS England to ensure it could 
49 
50 accommodate this demand. Third and fourth, networks for service provision  would 
51 have to be created in order to guarantee that appropriate    screening and monitoring 
52 
53 structures were in place for hepatitis C patients (NICE,   2014a). 
54 
55 Although NHS England’s request downplayed the expected budget impact of 
56 sofosbuvir as a reason for the request–because budget impact is not an eligible reason 
57 
58 for  such  extensions  under  the  legal  framework  set  by  the  government–the ensuing 
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1 
2 
3 protest   suggests   that  stakeholders  agreed  that  it   was   a   veiled  request  based  on 
4 
5 concerns about budget impact (NICE, 2014b). The submissions by NHS England 
6 suggest  that  such  views  were  not  far-fetched.  According  to  NHS      England’s 
7 
8 submission:   “[…]   at   the   prices   proposed   by   the   manufacturer   in   their NICE 
9 
10 submission, this technology is not affordable at the quantum of    new expenditure it 
11 would represent”  (NICE, 2014,  p. 8).  Consultees were  given the  opportunity    to 
12 
13 comment  on  NHS  England’s  request.  One  patient  organization  summarized       the 
14 
15 problems as follows: 
16 The Hepatitis C Trust objects in the strongest possible terms to any attempt to 
17 introduce budget as a factor. If we are going to change  our health care 
18 resource  allocation  model  to  one  based on  arbitrary consideration  of this 
20 year’s budget, then this should be debated nationally, preferably through   an 
21 election manifesto. Either NICE has a mandate to decide resource  allocation 
22 or it doesn’t (The Hepatitis C Trust, 2014, p. 6). 
23 
24 
25 The submissions in response to NHS England’s request to delay the date  by 
26 which sofosbuvir has to be made accessible highlights complex questions about  the 
27 
28 how   the   ability   of   NICE’s   decision-making   framework   to   accommodate   cost 
29 
30 effectiveness and affordability is perceived by stakeholders. The patient 
31 representatives raised the issue that if budget impact is an implicit consideration   in 
32 
33 cases such as sofosbuvir, then this has to be made explicit and deserves debate in the 
34 
35 wider public and political policymaking  arena. 
36 
37 
38 South Korea 
39 
40 
41 The Republic of Korea has a National Health Insurance Service (NHIS) that 
42 
43 covers 96.6% of  the population  (OECD,  2012).  The rest  of the  population is covered 
44 
45 “[…]    by a medical aid plan which is directly funded by […] the national and local 
46 governments […]” (Ahn, 2012, p. 344). While the NHIS is known for its population- 
47 
48 based universal coverage, the benefits that are  covered are  limited and     out-of-pocket 
49 
50 payments were at 36.9% in 2013 (OECD, 2015) even though the benefit coverage has 
51 expanded since the 1990s. 
52 
53 In  2012 the  NHIS set  up  a lay citizen’s council,  the  Citizen Committee     for 
54 
55 Participation, made up of lay members of the public who are selected following   an 
56 application process. Although still in its early years, the decision-making mechanism 
57 
58 of  the  Committee,  and its  influence  on  the  final  decisions  by  the  Health Insurance 
  
 
 
1 
2 
3 Policy  Committee (HIPC),  are considered  significant.  In  its first  year  69%  of newly 
4 
5 covered services were originally chosen and recommended by the Citizen Committee 
6 (Oh et al., 2015). However, except for the Citizen Committee, PPI is not prominent in 
7 
8 Korea  unless  a  nationwide  interest  develops  that  puts  pressures  on  adopting    new 
9 
10 health technologies, especially pharmaceuticals. Such was the case with sofosbuvir. 
11 The case of sofosbuvir reached the public agenda not through the Citizen 
12 
13 Committee,  but through  a  scandal  that  rocked  a clinic  in  Seoul in  November 2015. 
14 
15 Sofosbuvir was approved  by the  regulatory authority in  September 2015  (MFDS, 
16 2015). A scandal arose in a neighborhood in Seoul when an outbreak of HCV was 
17 
18 tied  to the  re-use of  disposable  needles at a  local clinic  specializing in     intravenous 
19 
20 (IV) injection services (Ah-young, 2015). According to the Korea Times (Ah-young, 
21 2015a), a total of 78 HCV infections were confirmed until the fourth of    December 
22 
23 2015 and 55 out of 78 patients were found to have type 1a, which is usually prevalent 
24 
25 in less than 1% of the hepatitis C patients in Korea (Seong et al., 2013). Many 
26 Koreans learned about the disease and the treatment option of sofosbuvir and its 
27 
28 combination drug from news reporting on a massive scale and they were sympathetic 
29 
30 to the victims of unethical medical practices. The incident elevated the issue of 
31 sofosbuvir  to  the  national  political  arena,  with  public   and  advocacy      groups 
32 
33 campaigning for access to the new medicines. The coincidence of this event and the 
34 
35 reimbursement review process of these drugs finally resulted in the Ministry of Health 
36 and Welfare asking for a faster review of sofosbuvir (The DailyPharm, 2015). 
37 
38 The  Korean  experience  highlights  additional  ethical  issues  that  characterize 
39 
40 the  debate  on  new  hepatitis  C  drugs,  namely  issues  of  fairness,     government 
41 accountability and public responsibility when infections occur due to unsafe medical 
42 
43 practices. This is the case in the recent scandal in Korea, but similar examples can be 
44 
45 found  in  other  countries,  for  example  in  the  UK  where   contaminated     blood 
46 transfusions in the 1980s led to increased HCV infections. Even though this issue did 
47 
48 not  emerge  as  a  result  of  formalized  PPI  processes,  the  public  outcry  in     Korea 
49 
50 underlines the effectiveness of public campaigns in the face of such scandals. The 
51 final reimbursement decision is  outstanding at the time  of writing,  but given    the 
52 
53 scandal and the ensuing public reaction, it is unlikely that the formalized PPI process, 
54 
55 if pursued by the decision-making authorities, will lead to any recommendation other 
56 than to reimburse sofosbuvir. 
57 
58 
  
 
 
1 
2 
3 The USA: The Institute for Clinical and Economic   Review 
4 
5 
6 Due to the fragmented nature of the American health care system there is no 
7 
8 one   government-mandated   institution   for   health   priority-setting.   Following    the 
9 
10 introduction of the Patient Protection and Affordable Care Act in 2010, the health 
11 care system remains a predominantly private system but the percentage of uninsured 
12 
13 continues   to   drop   (The   Commonwealth   Fund,   2015).   There   are   two   publicly 
14 
15 subsidized and federally managed health care programmes, namely Medicare for the 
16 elderly population over 65 and Medicaid for families meeting low-income eligibility 
17 
18 criteria (The Commonwealth Fund, 2015). Given the lack of institutionalized priority- 
19 
20 setting, this section examines the experience of an independent research body, the 
21 Institute for Clinical and Economic Review (ICER)
2
, that produces evidence reports 
22 
23 on new medicines, on which payer organizations such as insurers   draw. 
24 
25 The Institute for Clinical and Economic Review is an independent  research 
26 institute funded largely by non-profit foundations. It produces evidence reports    on 
27 
28 medical technologies to help guide the application of evidence to clinical practice and 
29 
30 insurance coverage policy (ICER, 2014). The Institute has created 
31 regional committees  of  independent  clinicians  and  public  representatives, called 
32 
33 Comparative Effectiveness  Public Advisory Councils (CEPAC),  who are convened   to 
34 
35 deliberate on evidence reports in meetings open to the public (ICER, 2016).       The 
36 meetings are spent debating the evidence, after which the CEPAC votes on  whether 
37 
38 the  evidence  is  adequate  to  demonstrate  that a  new technology  is  as  good or better 
39 
40 than  other  options  available  to  patients.  The  reports  include  evidence  on  cost 
41 effectiveness and potential budget impact and the Institute asks the CEPAC groups to 
42 
43 vote on the "value" of new  interventions. 
44 
45 The Institute’s draft evidence report on the HCV medicines received criticism 
46 from patient advocacy groups focused predominantly on the results of the economic 
47 
48 analyses that found that these drugs would not reduce long-term costs in the health 
49 
50 care system while presenting huge potential short-term costs that could   overwhelm 
51 health care budgets (ICER, 2014a). At the public CEPAC meeting, the CEPAC voted 
52 
53 that  the  evidence  was  adequate  to  demonstrate  the  clinical  superiority  of  the  new 
54 
55 
56 2 In order to avoid confusion between the incremental cost effectiveness ratio (ICER) and the 
57 Institute for Clinical and Economic Review (also ICER), this article does not use the ‘ICER’ 
58 abbreviation for the Institute, but refers to it as the ‘Institute’ or spells out its full name. 
  
 
 
1 
2 
3 drugs  but  that  they  represented  a  "low"  value  to  the  health  care  system
3      
(ICER, 
4 
5 2014b). The  voting  stage  of  the  meeting  was  followed  by  a  so-called    policy 
6 roundtable, an invited group composed of representatives from insurers, 
7 
8 manufacturers, clinical experts and patients. The roundtable included the leader of    one 
9 
10 of the patient groups. This representative criticised the vote of the CEPAC and sought 
11 to cast aspersions on the clinical expertise, primary motives, and financial interests of 
12 
13 all involved (ICER, 2014c).   The clinical experts responded by expressing their    belief 
14 
15 that, for clinical and economic reasons, the most reasonable path forward was to 
16 prioritize patients for treatment, with sicker patients receiving treatment first (ICER, 
17 
18 2014c). They felt this was reasonable not only because the short-term clinical risks 
19 
20 were minimal, but because there was inadequate infrastructure to treat all patients 
21 immediately and because the financial repercussions of immediate treatment for  all 
22 
23 eligible patients was unrealistic (ICER,  2014c). 
24 
25 The recommendation to use severity of initial liver damage as a method of 
26 prioritizing patients was the recommendation that was included in the final  CEPAC 
27 
28 report   (ICER,   2014).   The   patient   advocacy   organizations   did   not   accept   this 
29 
30 recommendation  and  opposed  it  in  the  press  (Clary,  2015).  But  private      and 
31 public health insurers felt empowered to establish their initial coverage 
32 
33 recommendations  to  mirror  this  approach,  and  many  cited  the  CEPAC  report     as 
34 
35 justification (e.g. UnitedHealthcare, 2014). Anecdotally, many insurers informed the 
36 Institute that having a transparent, independent process for evidence review was 
37 
38 important  to  their  decision-making.  Even  if  patient advocacy  groups  disagreed with 
39 
40 the result, insurers felt that the overall process had enough legitimacy to serve as   a 
41 cornerstone of their coverage policies. 
42 
43 The  case  underlines  complex  questions  about  the  purpose  of  PPI  and    the 
44 
45 legitimacy of prioritization  decisions. While  insurers  found the  Institute’s process 
46 helpful, the protests by patient advocacy groups suggest    that they did not view the 
47 
48 CEPAC  vote  as a fair outcome  of a  legitimate  process.  The  extant literature  on  the 
49 
50 legitimacy of decision-making processes in health priority-setting converges on  the 
51 idea that outcomes of decisions are more legitimate if the public has been   involved 
52 
53 (Daniels  and  Sabin,  1997;  Abelson  et  al.,  2007;  Parkinson,  2003).  However,    the 
54 
55 
56 3 Please note that this section is an account from one of the co-authors who is the Director of 
57 the Institute and was present in the deliberations. The full summary of the proceedings can be 
58 found on the Institute’s website (ICER, 2015). 
  
 
 
1 
2 
3 experience of the Institute for Clinical and Economic Review in the case of HCV 
4 
5 medicines suggests that enhancing the legitimacy of decision-making processes   of 
6 independent review bodies in the eyes of public and patient representatives remains a 
7 
8 challenging issue. 
9 
10 
11 Discussion  and Conclusion 
12 
13 
14 
15 Examining PPI in the case of sofosbuvir across multiple and diverse settings 
16 highlights that  none of the countries included in this paper diverted from their 
17 
18 established  modes  of  involving  the  public  and  patients.  These  modes  need  to   be 
19 
20 viewed in the political and historical contexts of the respective countries. They led to 
21 different,  yet  very  important,  questions  that  need  to  be  addressed.  In England, 
22 
23 stakeholders  stressed  the  controversies  that  arise when  cost  effective  medicines are 
24 
25 not covered within the statutory timeframe due to budget impact concerns, even 
26 though such a delay is statutorily permitted in certain circumstances. This   suggests 
27 
28 that  the   methodological  approach  employed   by  NICE   does   not  sit  easily     with 
29 
30 stakeholders. The public consultation process highlighted this issue, but it cannot be 
31 resolved in the currently available PPI forums. It is a political question that needs to 
32 
33 be addressed in the wider public  space. 
34 
35 In  South   Korea,  a  scandal  pre-empted  potential  deliberations  by      the 
36 established Citizen Committee of Participation. The Korean example brings to    the 
37 
38 forefront   the   importance   of   what   Slutsky   et   al.    (2016)    label      ‘contestatory 
39 
40 participation’ and of the  significant pressure  that media  campaigns  can exert    on 
41 decision-making  in  health  priority-setting.  It  remains  to  be  seen  how  the story 
42 
43 unfolds,  but  it seems  likely that the established forums  of PPI  will not  deviate   from 
44 
45 the public perception that the novel HCV medicines should be made available in the 
46 light of unethical medical practices. The Korean example is as much a story of 
47 
48 successful pressure exerted through media spaces as it is an example of how an issue 
49 
50 can reach the policy agenda and exacerbate the challenges faced by policymakers. 
51 The experiences of the USA and Brazil countries underline the importance of 
52 
53 national  context.  The  deliberative  meetings  held  by  the  Institute  for  Clinical    and 
54 
55 Economic Review fill a void in a fragmented health system in which insurers, the 
56 public and  patient advocacy  groups  have  little  guidance  on which  to draw when 
57 
58 making  tough  decisions  or  engaging  with  each  other.  The  Institute’s      experience 
  
 
 
1 
2 
3 accentuates  the  role  that  deliberative  processes  can   play  in  evaluating     evidence. 
4 
5 However, it also shows how challenging it is for these processes to be viewed as 
6 legitimate  by all those  involved (Kieslich and Littlejohns,  2015),  and failing     to 
7 
8 establish  legitimacy  is  a  real  barrier  to  the  contribution  that  public     participation 
9 
10 activities can make. In Latin America, PPI takes places in the context of national 
11 health systems that guarantee a right to health. The public and the patients insist  on 
12 
13 their  right  to  health and policymakers are faced with  the constraints that  this   system 
14 
15 puts on policies that seek to introduce efficiency savings. 
16 In conclusion, has the PPI experience in Brazil, England, South Korea and the 
17 
18 USA   helped  address   some   of   the   difficult  challenges  that  arise   in   the case  of 
19 
20 sofosbuvir? The short answer is no. The country experiences are as much a tale of 
21 challenges that arise when making difficult prioritization decisions as they are a tale 
22 
23 of agenda-setting. With regard to the unconventional modes of participation such as 
24 
25 protests and litigation, this observation is not surprising as they tend to receive much 
26 attention in the media. However, with regard to the more conventional modes of 
27 
28 participation through consultation and deliberation,    this observation is interesting as it 
29 
30 may suggest an agenda-setting role for the public even when this is not the   explicit 
31 purpose of these modes of participation. PPI on sofosbuvir has brought a number of 
32 
33 issues to, or back on, the policy agenda. In England, policymakers need to address 
34 
35 what NICE’s cost effective paradigm implies for a cash-strapped NHS. The American 
36 experience suggests it may be time for policymakers to think about how they can help 
37 
38 insurers  and  providers  establish  decision-making  processes  that  are  perceived     as 
39 
40 legitimate by the public. In South Korea, the importance of combining ethical and 
41 budgetary considerations has been underlined, especially when patients are infected 
42 
43 with HCV through no fault of their own. In Latin America policymakers are having to 
44 
45 strike the balance between realizing the right to health and the necessity to ensure the 
46 sustainability of health care systems (Ferraz, 2011). Of course, whether these issues 
47 
48 find  traction on  the  policy  agenda  depends on the  receptiveness and  willingness   of 
49 
50 policymakers to engage with them, and this question is an area for further research. 
51 The possible role of issue characteristics (Lowi, 1964; Burgin, 1995) also 
52 
53 merits  attention  in  future  research.  Lowi  (1964)  argues  that  variations  in    policy- 
54 
55 making processes can be explained with reference to the character and type of issues 
56 that are being addressed. In the case of pharmaceutical products issue characteristics 
57 
58 include  the  disease  area,  the  population  affected,  cost  effectiveness,  budget impact 
  
 
 
1 
2 
3 and  questions  of  equity.  The  question  that  demands  further  exploration  is whether 
4 
5 certain  characteristics  of  issues  brought  forth  by  cases  such  as  the  new  HCV 
6 medicines call for a stronger, or a particular mode of public involvement. Given  its 
7 
8 large  budget  impact,  views  from  the  wider  public  could  be  gained  on  the  kind of 
9 
10 trade-offs they would be willing to make if access to the new hepatitis C medicines is 
11 to be provided. However, constructing a case for a stronger, or a particular mode  of 
12 
13 public involvement, will rest on the resolution of at least three arguments against   it. 
14 
15 First, the discussed issues are not new or unique to HCV medicines. They are 
16 simply more pronounced in this case. The novel HCV drugs have brought to light the 
17 
18 challenging   issues   that   have    long   concerned   policymakers,    practitioners    and 
19 
20 academics. To use these challenges as an argument for going beyond existing modes 
21 of PPI would run the risk of establishing a case of exceptionality that may not be 
22 
23 justified.  Second,  existing modes of involvement or participation all come  with    their 
24 
25 own advantages, disadvantages and risks (Weale et al., 2016). Regardless of how 
26 carefully a particular mode of involvement is chosen, chances are that none of them 
27 
28 can address the entire breadth of issues. Third, isolating the situations in which issue 
29 
30 characteristics exacerbate the challenges of decision-making to such an extent   that 
31 warrants for taking the issues to the public at large would be difficult. Nevertheless, 
32 
33 the  complex  trade-offs  emerging  in  priority-setting  decisions  on  HCV     medicines 
34 
35 suggest  that  the  normative  and  empirical  role  of  issue  characteristics  is  worth 
36 exploring. 
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